Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03217071 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by Sue Yom.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT03217071: Completed Phase 2 study, sponsored by Sue Yom.
NCT03217071 is a Phase 2 study that has completed, run by Sue Yom. The registered enrollment target is 12 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03217071, a Phase 2 study, has completed, sponsored by Sue Yom.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
This is a randomized single-institution, phase II, open-label clinical trial of neoadjuvant pembrolizumab with or without low-dose stereotactic radiation therapy (SRT) in stage I-IIIA non-small lung cancer (NSCLC) patients who are planned to undergo surgical resection of their lung cancer.
Primary Outcome
The primary endpoint for this study is the change in the mean number of infiltrating CD3+ T cells/ μm2 in the lung cancer tissue from before and after pembrolizumab +/- SRT by group, based on quantification using immunohistochemistry (IHC) and image analysis by group.
Interventions
- DRUG Pembrolizumab
- RADIATION stereotactic radiation therapy (SRT)
- PROCEDURE Surgery (Non-interventional, standard of care)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2017-10-04 |
| Est. Completion | 2022-03-31 |
| Phase | Phase 2 |
What the finished NCT03217071 record still lists
NCT03217071 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT03217071 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03217071 about?
NCT03217071 is a clinical study titled "Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer". This is a randomized single-institution, phase II, open-label clinical trial of neoadjuvant pembrolizumab with or without low-dose stereotactic radiation therapy (SRT) in stage I-IIIA non-small lung cancer (NSCLC) patients who are planned to undergo surgical resection of their lung cancer.
What is the current status of trial NCT03217071?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2017-10-04. Estimated completion is 2022-03-31.
What interventions are being tested in trial NCT03217071?
The interventions under investigation include: Pembrolizumab (DRUG), stereotactic radiation therapy (SRT) (RADIATION), Surgery (Non-interventional, standard of care) (PROCEDURE).
Who is sponsoring clinical trial NCT03217071?
This trial is sponsored by Sue Yom, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03217071's enrollment target sits among peer trials
12 1948th of 2000 higher than 34 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI